We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Gazyva

News List

Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL pharmatimes
June 17, 2021
Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study.
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) biospectrumasia
September 18, 2019
Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies.
Chugai, Nippon Shinyaku bring Gazyva in Japan biospectrumasia
September 03, 2018
Chugai obtained a manufacturing and marketing approval in early July.
Roche nabs blockbuster FDA approval for Hemlibra, big label expansion for Gazyva fiercepharma
November 17, 2017
Hemlibra won the agency's backing to prevent or reduce bleeding in adults or children with hemophilia A who have developed antibodies called Factor VIII inhibitors.
FDA accepts Genentech’s sBLA for gazyva to treat untreated follicular lymphoma pharmaceutical-technology
August 30, 2017
The US Food and Drug Administration (FDA) has accepted biotechnology company Genentech’s supplemental biologics licence application (sBLA) and granted priority review for gazyva (obinutuzumab) for the treatment of untreated follicular lymphoma.